Table 3.
Comparison of the epidemiological and clinical characteristics of case patients and control patients aged > 1 year, Diyarbakır, 2012–2024
| Variable | Case patients (N:658) n (%)a |
Control patients (N:1974) n (%)a |
p-valueb |
|---|---|---|---|
| Age [median (Q1–Q3)], years | 6.2 (3.6–10.3) | 3.2 (1.6–6.5) | < 0.001 |
| Age group, years |
< 0.001 p-trend < 0.001 |
||
| 1–4 | 188 (28.6) | 1132 (57.3) | |
| 5–9 | 272 (41.3) | 571 (29) | |
| 10–14 | 78 (11.9) | 181 (9.2) | |
| 15–19 | 60 (9.1) | 36 (1.8) | |
| 20–24 | 23 (3.5) | 20 (1) | |
| ≥ 25 | 37 (5.6) | 34 (1.7) | |
| Sex | 0.71 | ||
| Female | 308 (46.8) | 908 (46) | |
| Male | 350 (53.2) | 1066 (54) | |
| Migrant status | < 0.001 | ||
| Non-immigrant | 617 (93.8) | 1916 (97.1) | |
| Immigrant | 41 (6.2) | 58 (2.9) | |
| Place of residencec | Valid: 163/658 | Valid: 652/1974 | 0.53 |
| Central districts | 139 (85.3) | 543 (83.3) | |
| Outlying districts | 24 (14.7) | 109 (16.7) | |
| Epidemic year | < 0.001 | ||
| Yes | 606 (92.1) | 1091 (55.3) | |
| No | 52 (7.9) | 883 (44.7) | |
| Season | < 0.001 | ||
| Autumn | 24 (3.6) | 269 (13.6) | |
| Winter | 73 (11.1) | 458 (23.2) | |
| Spring | 275 (41.8) | 537 (27.2) | |
| Summer | 286 (43.5) | 710 (36) | |
| Vaccination statusd | < 0.001 | ||
| Unvaccinated | 169 (25.7) | 181 (9.2) | |
| MCV1 | 118 (17.9) | 1076 (54.5) | |
| MCV1 + 2 | 4 (0.6) | 126 (6.4) | |
| Early dose | 1 (0.2) | 33 (1.7) | |
| Early dose + MCV1 | 4 (0.6) | 193 (9.8) | |
| Early dose + MCV1 + 2 | 0 (0.0) | 14 (0.7) | |
| Unknown | 362 (55) | 351 (17.8) | |
| Clinical symptomsc | |||
| Fever | Valid: 608/658 | Valid: 1714/1974 | < 0.001 |
| Yes | 556 (91.4) | 1261 (73.6) | |
| No | 52 (8.6) | 453 (26.4) | |
| Upper respiratory symptoms | Valid: 602/658 | Valid: 1682/1974 | < 0.001 |
| Yes | 482 (80.1) | 816 (48.5) | |
| No | 120 (19.9) | 866 (51.5) | |
| Lymphadenopathy/arthralgia | Valid: 301/658 | Valid: 1201/1974 | 0.004 |
| Yes | 18 (6) | 32 (2.7) | |
| No | 283 (94) | 1169 (97.3) | |
| Hospitalizationc | Valid: 651/658 | Valid: 1928/1974 | < 0.001 |
| Yes | 74 (11.4) | 125 (6.5) | |
| No | 577 (88.6) | 1803 (93.5) | |
Abbreviations: MCV, Measles-containing vaccine
aColumn percentages are presented
bP value for comparison between case patients versus control patients. Age compared using the Mann–Whitney U test; all other variables compared using Pearson’s chi-square test, Fisher’s exact test, or the chi-square test for trend
cFor variables with missing data, the number of individuals with available data out of the total number in each group is shown in the case patient and control patient columns. Percentages and p-values were calculated among individuals with available data
dEarly dose: MCV administered at 9–11 months of age; MCV1: one dose at ≥ 12 months; MCV1 + 2: two doses at ≥ 12 months